20/20 Biolabs Q2 Revenue Jumps 36% but Losses Widen; Cash at $4.5M
AIDX sits 39% above its 52-week low of $0.401 on light trading volume (0.3× avg).
Summary
20/20 Biolabs reported strong Q2 revenue growth but widening losses and ongoing internal control weaknesses. Cash improved to $4.5M, but the company remains reliant on toxic financing.
Updates
· GlobeNewswire — Gross margin expanded to 41.7% from 30.5%, and the company eliminated all convertible note debt. New state contracts in Vermont and Maryland plus a retail pilot with Giant Food signal expanding distribution.
Key Events · Earnings and Guidance · AIDX
-
Q2 Revenue Up 36.5%
Revenue reached $730,571, driven by OneTest sales to Maryland fire departments, up from $535,060 a year ago.
-
Net Loss Widens
Net loss attributable to common stockholders was $2.75M, up from $0.84M, due to higher operating expenses and a $1.12M deemed dividend on warrant modifications.
-
Cash Position Improves
Cash and equivalents rose to $4.55M from $1.03M at year-end, following a $6M private placement of Series E preferred stock.
-
Material Weaknesses Persist
Management disclosed ongoing material weaknesses in internal control over financial reporting related to insufficient accounting personnel and complex transaction expertise.
Analysis · AIDX · Industrial Applications And Services
20/20 Biolabs reported Q2 revenue of $730,571, up 36.5% year-over-year, driven by OneTest sales to Maryland fire departments. However, net loss attributable to common stockholders widened to $2.75M from $0.84M a year ago, and the company continues to operate with material weaknesses in internal controls. Cash improved to $4.55M after a $6M private placement, but the company remains dependent on toxic financing from Streeterville, with a standstill agreement limiting conversions for 120 days.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 36.5% of the 1062 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.61%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIDX was trading at $0.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.7M. The 52-week trading range was $0.40 to $50.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.